biostudies-literatureWhite MNNCI NIH HHSe210-e221https://www.ebi.ac.uk/biostudies/studies/S-EPMC12779337biostudies-literatureUnknown23(3)<h4>Introduction</h4>Patients with EGFR-mutant lung cancer who have had disease progression on osimertinib commonly receive platinum doublet chemotherapy, but whether adding immunotherapy or bevacizumab provides additional benefit is unknown.<h4>Materials and methods</h4>This was a retrospective analysis at 2 university-affiliated institutions. Patients with EGFR-mutant lung cancer who had progression on osimertinib and received next-line therapy with platinum doublet chemotherapy (chemo), platinum doublet chemotherapy plus immunotherapy (chemo-IO), or platinum doublet chemotherapy plus bevacizumab (chemo-bev), were identified; patients who continued osimertinib with these regimens were included. Efficacy outcomes including duration on treatment (DOT) and overall survival (OS) from the staClinical lung cancerChemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.PMC12779337P30 CA124435Piper-Vallillo AJCunanan KSequist LVNeal JWWhite MNPadda SKRamchandran KGardner RMChen TTPiotrowska ZWakelee HADas MfalseChemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.<h4>Introduction</h4>Patients with EGFR-mutant lung cancer who have had disease progression on osimertinib commonly receive platinum doublet chemotherapy, but whether adding immunotherapy or bevacizumab provides additional benefit is unknown.<h4>Materials and methods</h4>This was a retrospective analysis at 2 university-affiliated institutions. Patients with EGFR-mutant lung cancer who had progression on osimertinib and received next-line therapy with platinum doublet chemotherapy (chemo), platinum doublet chemotherapy plus immunotherapy (chemo-IO), or platinum doublet chemotherapy plus bevacizumab (chemo-bev), were identified; patients who continued osimertinib with these regimens were included. Efficacy outcomes including duration on treatment (DOT) and overall survival (OS) from the sta2022-01-01T00:00:00Z2022 May2026-06-06T12:46:06.371Z2026-05-30T03:11:40.11ZS-EPMC127793373488719310.1016/j.cllc.2021.11.001